Almac Discovery and RCSI enter research collaboration

By Melissa Fassbender

- Last updated on GMT

Graham Cotton, Senior R&D Group Leader, Almac Discovery; Tracy Robson; and Professor Tim Harrison, VP Discovery Chemistry, Almac Discovery.
Graham Cotton, Senior R&D Group Leader, Almac Discovery; Tracy Robson; and Professor Tim Harrison, VP Discovery Chemistry, Almac Discovery.

Related tags Oncology

Almac Discovery and the Royal College of Surgeons in Ireland (RCSI) and have announced a research collaboration aimed at understanding how to target therapy-resistant cancer tumors.

The collaboration will explore the potential of ALM201, which is currently undergoing a Phase I dose escalation trial for patients with solid tumors. The trial is expected to be expanded in a biomarker selected patient population within ovarian cancer.

ALM201 is peptide fragment of FKBPL that Almac Discovery has in clinical development​,” Martin Wiles, Vice President Business Development and Licensing at Almac Discovery told us.

The current plan is to investigate the anti-angiogenic properties in ovarian cancer patients; however this work is looking at a different angle on ALM201’s mode of action - that of inhibition of cancer stem cell/tumor initiation​,” he explained.

Tracy Robson, the initial researcher looking at FKBPL and its peptides who identified the stem cell aspect to ALM201’s mode of action, commented that the funding provided by Almac enables the researchers to better understand the mechanism behind ALM201’s anti-cancer stem cell activity.

We hope to obtain a more refined idea of the mode of action of ALM201 and to potentially be able to better select patients who will benefit from treatment with ALM201,” ​added Wiles.

Moving forward he explained, "The work will involve investigating if ALM201 has the means to reduce the initiation of tumors initially in the ovarian cancer setting​."

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars